More reads

• Trump budget pitches capping seniors’ out-of-pocket drug costs, cutting NIH funding. (STAT)
• The life, troubles, and Celgene legacy of deal guru George Golumbeski. (Xconomy)
• Axovant reaps the rewards from its gene therapy refocus. (EP Vantage)
• How algorithms could bring empathy back to medicine. (Nature)